National Immunisation Programme

Baroness Merron Excerpts

Thursday 18th January 2024 Grand Committee

[Baroness Merron (Lab)]

My Lords, I add my congratulations to my noble friend Lady Ritchie, who is as we all agree a great champion for better health through greater take-up and availability of vaccines and immunisation programmes. She rightly described them as a sound investment by the NHS, and I certainly agree.

There are two main issues at play: first, the failure of already approved and recommended drugs to be included in the national immunisation programme and, secondly, the number of factors that have slowed down how long the whole process takes. It potentially takes around a decade to pass through every stage of trial and approval and two years or more for a new vaccine to reach patients post regulatory authorisation.

I am sure that we all want vaccines to be available to patients quicker and to see full account taken of patient safety and cost effectiveness. It seems to me that the way forward is to emphasise systemic options to improve availability without sacrificing the necessary safeguards.

Like other noble Lords, I am grateful to the many stakeholders who have conveyed their views to me on how to accelerate the adoption of new innovative vaccines by the national immunisation programme. Their main suggestions for tackling these damaging delays focus on ensuring that the overall system works better while adapting to additional risk, perhaps in extraordinary circumstances, such as those we saw in the Covid pandemic.

But it bears pointing out that this is against the backdrop of a step in the wrong direction, which we have heard about, such that, due to a decade of declining rates of uptake of the MMR vaccination among preschool children, for example, the UK no longer has the status of having eradicated measles, according to the World Health Organization. This is borne out by Steve Russell, whom the noble Lord, Lord Allan, referred to; he is the chief delivery officer and national director for vaccinations and screening at NHS England. He highlights a decline in vaccination-programme uptake, particularly for childhood vaccinations, in the foreword to the NHS England strategy.

I thank my noble friend Lady Twycross for bringing before us the importance of childhood vaccination. She brought it into focus by sharing her own story, for which I am sure we all thank her, but her call for evidence-based intervention and for ensuring coverage by immunisation programmes surely must be heeded. It would be helpful to hear what discussions continue to take place across government about tackling misinformation and disinformation about MMR and other vaccines, which we obviously still see proliferating on social media.

I will put a few points to the Minister about the much-needed improvement of the UK’s performance in immunisation development and delivery. We heard from my noble friend Lady Ritchie about the GSK-hosted round table, which she kindly chaired. I noticed that she described the response during the Covid-19 pandemic as “remarkable” and I endorse her comments. That response magnified the value of vaccines to individuals, health systems, society and the economy, and it is absolutely vital to embed the lessons that were learned before they are lost, as she said. So I amplify the points made by my noble friend, because it would help to hear from the Minister about what lessons the Government have learned from the pandemic, what assessment they have made of the potential value of each of those lessons and what steps are being taken, at the very least, to assess the potential benefits from continuing in that manner, but ideally to take action to embed in the system all the good practice from which we have learned.

Within this, I echo the call for pharmacies to be complimented for rising to the challenge during the pandemic. They continue to play an increasingly key role in providing advice and healthcare, including convenient and accessible vaccination services. Does the Minister consider that community pharmacies can play an even larger role in immunisation programmes by expanding the range of vaccines that they can offer, including those for shingles, RSV and pneumonia? What steps are being taken to marshal the forces of community pharmacies and expand their potential as community well-being hubs?

The second point is a predictable issue with a bearing not on safety but on bureaucracy. I am aware of the potential complexities, but what steps are the Government taking to explore the adaptation of funding mechanisms to expected new programmes in order to avoid delays and issues because of the constraints of rigid envelopes and complex approval processes? What are the general steps in the areas of improving resourcing, co-ordination and process across regulators and health-technology assessment bodies?

There is an increasing focus on the role of vaccination in fighting AMR. The JCVI has shown some willingness to consider its impact in its value-assessment criteria. I suggest to the Minister that this could be an interesting development. Given that it is newer science, it would be interesting to hear from the Government what assessment they have made of the AMR-reduction benefit from vaccines and whether they are taking any steps to explore how it can be harnessed further.

With further reference to the JCVI, I want to raise the suggestion of evolving its work to better enable the adoption of innovative vaccines. Broadly, it is important that the JCVI is continuously looking ahead. Can the Minister indicate how the Government are working with JCVI to ensure this mode of travel?

I was very interested in the argument put forward by Policy Exchange that a busy pipeline of new vaccine technologies in the coming years, including a growing number of therapeutic as well as preventative candidates, coupled with a concerning decline—as we have discussed —in the uptake of key programmes such as MMR, necessitates a fresh look at the architecture and delivery model for vaccine development and deployment. Policy Exchange’s key recommendations on delivery include boosting ministerial oversight—I am sure the Minister will have a view on that; expanding the role for community pharmacy, which we have talked about many times in our Chamber; creating a new workforce model; and piloting a local delivery model called a “vaccine collaborative”. The positive and overarching principle behind those suggestions is that of extending care further into the community. It would be helpful to get a sense of the Government’s ambition in this area and the steps they are taking to move beyond traditional delivery mechanisms to make this improvement.

As I said at the beginning, we all want an improvement in the UK’s performance in immunisation development and delivery. I look forward to hearing the Minister’s response.